Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Medicine (Baltimore). 2021 Apr 2;100(13):e25309. doi: 10.1097/MD.0000000000025309.
Uterine leiomyosarcomas are rare malignant mesenchymal tumors. The systemic treatment of these tumors includes chemotherapy and radiotherapy. However, there are still a lot of unanswered questions regarding the ideal therapeutic approach.
We have conducted a systematic review of the treatment strategies of uterine leiomyosarcomas for the last ten years.
Adjuvant chemotherapy is still a matter of dilemma. Doxorubicin based chemotherapy or the combination of Gemcitabine-Docetaxel are the regimens of choice for the first line setting. Beyond the first line, there are several options;, including chemotherapy, targeted therapy, and recently efforts of introducing immunotherapy to the therapeutic armamentarium of clinicians treating uterine leiomyosarcomas.
Despite the efforts of the clinicians dealing with uterine leiomyosarcomas, the optimal therapeutic algorithm is yet to be described.
子宫平滑肌肉瘤是罕见的恶性间叶性肿瘤。这些肿瘤的系统治疗包括化疗和放疗。然而，对于理想的治疗方法仍有许多尚未解决的问题。
我们对过去十年中子宫平滑肌肉瘤的治疗策略进行了系统评价。
辅助化疗仍然存在争议。多柔比星为基础的化疗或吉西他滨-多西紫杉醇联合化疗是一线治疗的首选方案。在一线治疗之外，还有几种选择，包括化疗、靶向治疗，以及最近将免疫治疗引入治疗子宫平滑肌肉瘤的临床医生的治疗手段。
尽管治疗子宫平滑肌肉瘤的临床医生做出了努力，但最佳的治疗方案仍有待描述。
